Single pass defibrillation/pacing lead with passively attached electrode for pacing and sensing

Information

  • Patent Grant
  • 6321122
  • Patent Number
    6,321,122
  • Date Filed
    Wednesday, July 22, 1998
    26 years ago
  • Date Issued
    Tuesday, November 20, 2001
    23 years ago
Abstract
A single-pass endocardial lead electrode adapted for implantation on or about the heart and for connection to a system for monitoring or stimulating cardiac activity includes a lead body with a circumferential outer surface. The lead includes a first distal end electrode which has a first electrical conducting surface. The lead body also has a second electrode which has a second electrical conducting surface. The second electrode is adapted for positioning and fixation to the wall of the atrium of the heart. A passive fixation element may be used as part of the second electrode. The lead body also includes a curved portion which facilitates the positioning and passive fixation of the second electrode.
Description




RELATED APPLICATIONS




This patent application is related to an application entitled “SINGLE PASS LEAD HAVING RETRACTABLE, ACTIVELY ATTACHED ELECTRODE FOR PACING AND SENSING” which is assigned to a common assignee and is filed on a date even herewith. The related application is incorporated herein by reference.




FIELD OF THE INVENTION




The present invention relates to the field of leads for correcting arrhythmias of the heart. More particularly, this invention relates to a single lead which can simultaneously pace/sense and/or defibrillate two chambers of the heart.




BACKGROUND OF THE INVENTION




Electrodes implanted in the body for electrical cardioversion or pacing of the heart are well known. More specifically, electrodes implanted in or about the heart have been used to reverse (i.e., defibrillate or cardiovert) certain life threatening arrhythmias, or to stimulate contraction (pacing) of the heart, where electrical energy is applied to the heart via the electrodes to return the heart to normal rhythm. Electrodes have also been used to sense near the sinus node in the atrium of the heart and to deliver pacing pulses to the atrium. An electrode positioned in any chamber of the heart senses the electrical signals that trigger the heartbeat. Electrodes detect abnormally slow (bradycardia) or abnormally fast (tachycardia) heartbeats. In response to the sensed bradycardia or tachycardia condition, a pulse generator produces pacing or defibrillation pulses to correct the condition. The same electrode used to sense the condition is also used in the process of delivering a corrective pulse or signal from the pulse generator of the pacemaker.




There are four main types of pulses or signals which are delivered by a pulse generator. Two of the signals or pulses are for pacing the heart. First of all, there is a pulse for pacing the heart when it is beating too slowly. The pulses trigger the heart beat. These pulses are delivered at a rate to increase the abnormally low heart rate to a normal or desired level. The second type of pacing is used on a heart that is beating too fast. This type of pacing is called antitachycardia pacing. In this type of pacing, the pacing pulses are delivered initially at a rate much faster or slower than the abnormally beating heart until the heart rate can be returned to a normal or desired level. The third and fourth types of pulses are delivered through large surface area electrodes used when the heart is beating too fast or is fibrillating, respectively. The third type is called cardioversion. This is delivery of a relatively low energy shock, typically in the range of 0.5 to 5 joules, to the heart. The fourth type of pulse or signal is a defibrillation signal which is the delivery of a high energy shock, typically greater than 25 joules, to the heart.




Sick sinus syndrome and symptomatic AV block constitute the major reasons for insertion of cardiac pacemakers today. Cardiac pacing may be performed by the transvenous method or by electrodes implanted directly onto the epicardium. Most commonly, permanent transvenous pacing is performed using one or more leads with electrodes positioned within one or more chambers of the heart. The distal end of a lead, sometimes referred to as a catheter, may be positioned in the right ventricle or in the right atrium through a subclavian vein. The lead terminal pins are attached to a pulse generator which is implanted subcutaneously.




Some patients require a pacing system to detect and correct an abnormal heartbeat in both the atrium and ventricle which may have independent rhythms, as well as a defibrillation system to detect and correct an abnormally fast heart rate (tachycardia condition). In the past, a common practice for a patient having to pace both of these chambers would be to provide two different leads attached to the heart. One would be implanted for delivering pacing/sensing/defibrillating to the ventricle and one to the atrium to both pace and sense.




Having two separate leads implanted within the heart is undesirable for many reasons. Among the many reasons are that the implantation procedure for implanting two leads is more complex and also takes a longer time when compared to the complexity and time needed to implant a single lead. In addition, two leads may mechanically interact with one another after implantation which can result in dislodgment of one or both of the leads. In vivo mechanical interaction of the leads may also cause abrasion of the insulative layer along the lead which can result in an electrical failure of one or both of the leads. Another problem is that as more leads are implanted in the heart, the ability to add other leads is reduced. If the patient's condition changes over time the ability to add leads is restricted. Two separate leads also increase the risk of infection and may result in additional health care costs associated with re-implantation and follow-up.




Because of these problems, catheters having electrodes for both pacing and sensing in both chambers of the heart on a single lead body have been used. These leads, known as single pass lead designs, have drawbacks since the single pass lead designs utilize “floating” electrodes or electrodes which are not attached to the endocardial wall of the heart. The catheter having the electrodes which forms the lead body is essentially straight. The electrode or electrodes may float or move slightly at a distance from the endocardial wall within the heart.




The portion of the lead positioned within the atrium of current single-pass endocardial leads has one or more electrodes which are incorporated into the lead body as an electrically conductive cylindrical or semicylindrical ring structure. In other words, the lead body is basically cylindrical and the one or more electrodes positioned within the atrium of the heart are cylindrical metal structures incorporated into the cylindrical lead body. The ring electrode structures do not allow for tissue ingrowth into the electrode to enhance electrode stabilization within the atrium. Since the location of the electrodes is not fixed against the atrial wall, the performance of these leads is more variable. In other words, variations with respect to electrical contact with the wall of the atrium results in suboptimal electrical sensing capability and pacing delivery capability. Typically, the pacing characteristics of a floating electrode are less desirable than the pacing characteristics associated with an electrode fixed to the endocardial wall of the heart. The performance of a lead using a floating electrode is poorer than a lead having electrodes which contact or are nearer the walls of the heart.




Another problem associated with the current straight single pass leads, is that these electrodes may be unable or less able to sense an arrhythmic condition. In addition, the applied voltage or current needed for pacing may be ineffective. Additional energy may have to be used to pace the heart thereby depleting energy from the battery of the pulse generator of the pacing system.




There is a real need for a single-pass transvenous pacing or defibrillation lead. A single-pass lead equipped with such an electrode arrangement would allow for better sensing capability and better pacing therapy to the heart. In addition, there is a need for a single-pass lead having an electrode for positioning within the atrium that allows for tissue ingrowth. Such an electrode would further enhance lead stabilization within the heart. There is also a need for a single-pass endocardial lead which has an electrode for placing within the right atrium of the heart that accommodates eluting anti-inflammatory drugs. There is still a further need for a single pass endocardial lead that is easier for a surgeon to implant.




SUMMARY OF THE INVENTION




A single-pass endocardial lead electrode adapted for implantation and for connection to a system for monitoring or stimulating cardiac activity includes a lead body with a circumferential outer surface. The lead includes a first distal end electrode or electrode pair which has a first electrical conducting surface. The lead body also has a second electrode or electrode pairs which has a second electrical conducting surface. The second electrode or electrode pair is adapted for positioning and fixation to the wall of the atrium of the heart. A passive fixation element is used as part of the second electrode or electrode pair. The lead body also includes a curved portion which facilitates the positioning and fixing of the second electrode or electrode pair. The curved portion has a radius near the natural radius of the atrium. The first and second electrode may be a single electrode or a bipolar pair. The curve in the lead body, which is positioned in the right atrium of the heart after implantation, positions the electrode closer to the wall of the atrium to enhance the sensing and pacing performance of the lead.




The electrical conducting surface of the second electrode has a relatively small diameter when compared to previous electrodes. The small diameter electrode results in superior electrical performance when compared to previous single-pass endocardial leads. The benefits include increased pacing impedance, increased P-wave signal amplitudes and decreased atrial pacing capture thresholds. The increased impedance lets the battery energy source last longer. The single-pass lead equipped with an atrial electrode capable of being fixed to the endocardial wall allows for better sensing capability and better current delivery to the heart. The second electrode may be placed on the outside of the curved portion of the lead body. The fixed atrial electrode enhances lead stabilization within the heart. The result is no need for two leads in the heart. The costs and complexity associated with implanting and follow-up care for the single pass lead is less than two separate leads.











BRIEF DESCRIPTION OF THE DRAWINGS





FIG. 1

is a side view of the dual chamber single pass lead with dual chamber sense pace and antitachyarrhythmic therapy for electrically stimulating the heart.





FIG. 2

is a side view of the single-pass endocardial lead for sensing and electrically stimulating the heart, positioned within the right ventricle and right atrium of the heart.





FIG. 3

is a view of a dual chamber single pass endocardial lead having a passive attachment element on the curved portion of the lead.





FIG. 4

is a perspective view of the atrial electrode portion of the lead showing a passive attachment element for attachment to the atrial wall of the heart.





FIG. 5

is a side view of another embodiment of the electrode for passive attachment to the atrial wall of the heart.





FIG. 6

is a side view of another embodiment of the electrode for passive attachment to the atrial wall of the heart.





FIG. 7

is a side view of another embodiment of the electrode for passive attachment to the atrial wall of the heart.





FIG. 8

is a side view of another embodiment of the electrode for passive attachment to the atrial wall of the heart.





FIG. 9

is a side view of another embodiment of the electrode for passive attachment to the atrial wall of the heart.





FIG. 10

is a side view of another embodiment of the electrode for passive attachment to the atrial wall of the heart.





FIG. 11

is a side view of a portion of a lead body showing an electrode for passive attachment to the atrial wall of the heart.





FIG. 12

is a side view of the dual chamber single pass lead with dual chamber sense pace and antiarrhythmic therapy for electrically stimulating the heart.











DESCRIPTION OF THE PREFERRED EMBODIMENT




In the following detailed description of the preferred embodiments, reference is made to the accompanying drawings which form a part hereof, and in which are shown by way of illustration specific embodiments in which the invention may be practiced. It is to be understood that other embodiments may be utilized and structural changes may be made without departing from the scope of the present invention.





FIG. 1

is a side view of a lead


100


for delivering electrical pulses to stimulate the heart. The lead


100


is comprised of three basic portions, a connector terminal


110


, an electrode end


130


, and a portion


120


which interconnects the electrode end


130


and the connector terminal


110


. All three of these portions, the interconnection portion


120


, the electrode end


130


and the connector terminal


110


are constructed of conductive wires covered by a silicone rubber tubing which is biocompatible. Many times, the conductive wires within the silicone rubber tubing are referred to as the lead body


120


. The connector terminal


110


electrically connects the various electrodes and conductors within the lead body to a pulse generator


140


. The electrode end


130


is the portion of the lead


100


that includes electrodes and is positioned within the heart after implantation. The pulse sensor and generator


140


contains electronics to sense various electrical signals of the heart and also produce current pulses for delivery to the heart. The pulse sensor and generator


140


also contains electronics and software necessary to detect certain types of arrhythmias and to correct for them. The lead


100


shown in

FIG. 1

is a single pass endocardial lead and is capable of producing all types of pulses, including pacing pulses, antitachycardia pulses, cardioversion pulses and defibrillation pulses. The lead terminal connector


110


provides for the electrical connection between the lead


100


and pulse generator


140


.




The lead body


120


is cylindrical in shape. The lead body


120


is a tubing material formed from a biocompatible polymer for implantation, and preferably tubing made from a silicone rubber polymer. The silicone rubber polymer tubing contains several electrical conductors. The electrical conductors are made of a highly conductive, highly corrosion resistant material. Several separate electrical conductors are housed within the lead body


120


. The connector terminal


110


connects the various electrodes and conductors within the lead body to the pulse generator


140


.




After the lead


100


has been implanted, the electrode end


130


of the lead body


120


is situated predominantly within the heart. The electrode end


130


of the lead body


120


includes a curved or bias portion


150


and a straight portion


160


. After implantation, bias portion


150


of the electrode end


130


will generally be located in the right atrium of the heart. Generally, portion


160


will be located in the right ventricle.




The electrode end


130


of the lead


100


has four electrodes. The lead


100


shown in

FIG. 1

has two electrode pairs. One pair is located in the atrium and one pair in the ventricle. The first electrode


154


is provided at the farthest distal end of the lead for the purpose of delivering ventricular pacing therapy. The first electrode


154


is referred to as the RV pace/sense tip. A second electrode


153


is located proximate and proximal to electrode


154


and can be used as a counter electrode for


154


or as an electrode for defibrillation therapy. Electrode


153


is also known as the distal coil or the RV shock coil. The second electrode is actually a shocking coil and is much longer than the first electrode. A third electrode


161


is located at a more proximal position for the purpose of delivering atrial pacing therapy. Electrode


161


is also used for atrial sensing. Electrode


161


is also referred to as the atrial sense/pace electrode. This electrode


161


is intended to be passively attached to the atrial wall of the heart. A fourth electrode


162


is located proximate and proximal to electrode


161


and can be used with electrode


161


for atrial sensing/pacing and as counter to


153


as part of a defibrillation therapy system. Electrodes


153


and


162


are coils of a biocompatible metal or metal alloy such as, but not restricted to, platinum, or platinum/iridium. The coils are generally known as shocking coils and deliver large amounts of energy used in cardioversion and defibrillation. Electrode


162


is also referred to as the proximal coil or the SVC shock coil. The SVC shock coil


162


is positioned in the upper atrium or the superior vena cava. The atrial electrode


161


has a relatively small electrically active surface area. The advantages of this small surface area are high impedance for lower current drainage and a small lead cross section for ease of venous access and transport through the subclavian vein.




The shape of the curved portion


150


of the lead is important.

FIG. 2

shows the lead


100


and, more specifically, the electrode end


130


positioned within a heart


200


. The heart


200


includes four chambers which are the right atrium


202


, the right ventricle


204


, the left ventricle


206


and the left atrium


208


. Also shown in

FIG. 2

is the superior vena cava


210


. The electrode end


130


of the lead


100


is positioned within the superior vena cava


210


, the right atrium


202


and the right ventricle


204


. The curved portion


150


of the lead


100


positions the atrial sense electrode


161


on the curved portion or biased section


150


closer to the wall of the heart in the right atrium


202


. This enhances electrical performance as electrode


161


will be closer to the portion of the heart


200


, namely the right atrium


202


, where the signal will pass. In addition, the electrode


161


is positioned closer to the wall of the right atrium


202


such that passive fixation may be possible. If passive fixation is achieved, the electrode end


130


of the lead


100


will be more stably fixed within the heart


200


. If the passive fixation is not achieved, at least the electrode


161


will be closer to the wall of the right atrium


202


so as to enhance the electrical sensing capability of that electrode. Also, near the electrode


154


are a set of tines


180


. Tines


180


aid in positioning the electrode end


130


in the right ventricle


204


at the time of lead insertion. At the time of lead implantation, the distal electrode


154


is generally positioned in the right ventricle. Tines


180


are first needed to engage tissue structures which line the endocardial surface of the chamber


204


. This engagement holds the lead in place when first implanted. Later, fibrous tissue grows over these tines


180


over time to produce an attachment to the wall of the heart in the right ventricle


204


.





FIG. 2

also shows the lead terminal connector


110


and its connection into the pulse generator


140


. The lead terminal connector


110


makes electrical connection with a signal processing/therapy circuit


220


which in turn is electrically connected to a microcontroller


230


. Within the microcontroller


230


is a synchronizer


240


. The signal processing/therapy circuit


220


determines the type of therapy that should be delivered to the heart


200


. The microcontroller


230


controls the delivery of the therapy to the heart through the synchronizer


240


. The synchronizer


240


times the delivery of the appropriate signal to the heart.





FIG. 3

shows a lead


300


used to treat a bradycardia condition. The lead


300


differs from the lead


100


in that there is no proximal or SVC shock coil, and no distal shock coil. The reference numerals associated with the lead


100


which describes similar parts have been used here for the purposes of simplicity. The lead


300


includes a distal or RV pace sense tip


154


, an atrial sense electrode


161


, and a ring electrode


310


. The electrode end


130


of the lead


300


includes a straight portion


160


and a curved portion


150


. The atrial sense electrode


161


is positioned on the portion


150


. Portion


150


is curved. This allows the atrial sense electrode


161


to be positioned closer to the wall of the atrium of the heart. The atrial sense electrode


161


can also be provided with a means for passive fixation to the wall of the heart. In this unipolar application, the distal tip electrode


154


serves as the negative pole and the pulse sensor and generator


140


serves as the positive pole when a pacing pulse is delivered to the right ventricle of the heart. It should be noted that this is not the only possible unipolar arrangement, but that other unipolar arrangements are possible. Furthermore, it should be noted that a bipolar arrangement may also be used. Also, it should be noted that the electrode


161


is placed on the curved portion


150


of the lead


300


. The placement is important in that the electrode


161


that is used for pacing and sensing points out in the direction of the bias of the curved portion


150


. In other words, the electrode


161


is on the larger radius of the curved portion


150


of the lead. This assures that the distance between the electrode


161


and the wall of the atrium


202


is minimized. This also maximizes the possibility that the electrode


161


will become passively fixed to the wall of the heart. The outside surface of the curved portion


150


of the lead


300


can be textured to further enhance the passive fixation of the lead


161


to the heart.




The ring electrode


310


is also placed a selected distance from the electrode


161


. The ring electrode


310


has the opposite polarity of the electrode


161


. The ring electrode


310


is placed so that it is near the superior vena cava of the heart when the lead


300


is placed in the heart. The electrodes


310


and


161


are used as a bipolar pair for sensing and pacing. The lead


300


is a single pass lead that can be used for both sensing a bradycardia condition and treating it by pacing.





FIGS. 4-11

further detail certain elements of the passive fixation single pass electrode used as electrode


161


.

FIG. 4

shows a conductive ring made of a highly conductive, and highly corrosion resistant, material such as an alloy of platinum-iridium. The ring


401


includes a small porous tip electrode


402


. The ring


401


is electrically insulated from body fluids. The porous tip electrode is electrically active and in contact with body fluids and tissue. The active porous tip electrode


402


includes a screen of porous conductive material such as the alloy of platinum and iridium. Over time, the tissue encapsulation grows into the screen made of a platinum-iridium alloy to attach the electrode or electrodes to the endocardial wall of the heart. The electrode


161


has a nominal radius of 0.04 inches (1 mm). The advantage of this small radius is ease of venous access and high impedance for conserving pacing energy. Saving energy makes the battery used to power the pulse generator


140


last longer.





FIG. 5

shows another passive fixation electrode.

FIG. 5

shows a conductive ring


501


made of a highly corrosion-resistant material such as an alloy of platinum and iridium. The ring includes two small porous tip electrodes


510


and


511


. The ring


501


is electrically insulated from body fluids. The porous tip electrodes


510


and


511


are electrically active and in contact with body fluids. The active porous tip electrodes


510


and


511


each include a screen of porous conductive material made of the highly corrosion-resistant alloy of platinum and iridium. As with the electrode shown in

FIG. 4

, tissue encapsulation grows into the screen on the tips


510


and


511


to attach the electrode to the endocardial wall of the heart.





FIG. 6

shows another passive fixation element associated with the electrode


161


.

FIG. 6

shows a conductive ring


601


again made of a highly conductive corrosion-resistant material. The ring


601


includes a porous tip electrode


610


. The ring


601


is electrically insulated from body fluids. The porous tip electrode


610


is electrically active and in contact with body fluids. The porous tip


610


in

FIG. 6

is larger than the porous tip


402


shown in FIG.


4


. The porous tip


610


is made of corrosion-resistant material and is a screen. When the porous tip


610


lays against the endocardial wall of the heart, the tissue of the heart encapsulates and grows into the screen to passively attach the electrode to the heart.





FIG. 7

shows a variation of the electrode shown in FIG.


6


.

FIG. 7

shows a conductive ring


701


also made of highly conductive material. The conductive ring


701


includes a first porous tip


710


and a second porous tip


711


. The ring


701


is electrically insulated from body fluids. The porous tip electrodes


710


and


711


are electrically active and in contact with body fluids. The porous tips are also made of highly corrosion-resistant material. Like the previous conductive rings shown, the tissue of the heart encapsulates and grows into the porous screen in order to provide passive attachment of the electrode to the endocardial wall of the heart.





FIG. 8

shows that a smooth ring


800


can also be used as the main element of the electrode


161


in the curved portion


150


of the lead


100


. The smooth ring is made of a corrosion-resistant material that is highly conductive. All of the ring can be exposed or a portion of it can be masked or insulated, so that portion is nonconductive.





FIG. 9

shows another variation and includes a ring


900


. In

FIG. 9

, surface


910


is comprised of layers of conductive mesh or other porous materials attached to the ring


900


. The layers of conductive mesh create an active surface for pacing and sensing and a layer for enhanced tissue ingrowth. Alternatively, texturization or other surface treatment could be applied to ring


900


to enhance tissue ingrowth.





FIG. 10

shows a modified raised ridge type of electrode. In this particular application, the layers of conductive porous material are deposited on a thin band rather than across the entire width of the ring.

FIG. 10

shows a ring


1000


made of highly conductive material insulated from body fluids. The thin band is electrically active. The remaining portion of the ring


1000


is insulated. Attached to the ring is a raised ridge


1010


. All of the ring


1000


can be exposed or a portion of it can be masked or insulated so that portion is nonconductive.





FIG. 11

shows an portion of a lead


1100


which includes a porous tip type of electrode


1110


(like those shown in

FIGS. 4 and 5

) which is not mounted on a ring. The porous tip electrode


1110


is placed in either a straight or curved portion of the lead. The porous tip electrode


1110


is placed directly into the surface of the lead. An electrical conductor


1112


is attached to the electrode. The surface of the lead near the electrode


1120


may be textured to enhance the ability of the lead to become passively fixed to the wall of the heart.





FIG. 12

is a side view of the dual chamber single pass lead with dual chamber sense pace and antiarrhythmic therapy for electrically stimulating the heart.

FIG. 12

is similar to the lead shown in FIG.


1


. As a result, the common elements will not be discussed here since reference may be had to the discussion of

FIG. 1

above. The main difference between the lead shown in FIG.


1


and the lead shown in

FIG. 12

is the electrode


1210


. This is a fifth electrode on the lead. The electrode


1210


is positioned on the lead so that there are two sensing electrodes,


161


and


1210


in the atrium of the heart to enhance the sensing capability of this lead.




It should be noted that even though various rings are shown in

FIGS. 4-10

, the pacing and the sensing tip can be mounted to the curved portion


150


of the lead


100


or the lead


300


without a ring. In this instance, a tip would form the electrode


161


which is used as an atrial sense electrode. Once again, it should also be pointed out that the pacing and sensing tip points out in the direction of the bias or is on the portion of the lead body that is closest to the atrial wall of the heart. This positioning facilitates the electrical performance of the electrode


161


.




It is contemplated that slight variations in the design could be used for a particular application as required. One such variation would be the provision of steroid elution from any of the electrodes


153


,


154


,


161


and


1210


. Drug elution, typically steroid, can be provided by using one or more of the drug-releasing technologies such as sleeves or collars positioned in close proximity to the electrodes or by the use of internalized drug-containing plugs. An example of the composition of at least one collar is dexamethasone acetate in a simple silicone medical adhesive rubber binder or a steroid-releasing plug similarly fabricated.




The shape of the curved or bias portion


160


facilitates the placement of the atrial electrode against the atrial wall during implantation. The shape of the electrode end


130


will also be approximately the same before implantation as after implantation and the result will be that the shape reduces the nominal residual stresses in the lead body


100


.




It is to be understood that the above description is intended to be illustrative, and not restrictive. Many other embodiments will be apparent to those of skill in the art upon reviewing the above description. The scope of the invention should, therefore, be determined with reference to the appended claims, along with the full scope of equivalents to which such claims are entitled.



Claims
  • 1. A lead adapted for implantation in, on or about the heart and for connection to a system for monitoring or stimulating cardiac activity, said lead comprising:a lead body having a proximal end and a distal end, and a curved portion at a selected distance from the distal end of the lead body; a first electrode attached to the lead body at the distal end of the lead body for contact with a first chamber of the heart; and a second electrode attached to the lead body, the second electrode comprising an electrically conductive ring positioned a distance from the first electrode on the curved portion of the lead body to facilitate attachment of the second electrode to a second chamber of the heart, the second electrode including a passive fixation element.
  • 2. The lead as recited in claim 1, wherein the first chamber of the heart is the right ventricle of the heart and wherein the second chamber of the heart is the right atrium.
  • 3. The lead as recited in claim 2, wherein the second electrode comprises a porous ring.
  • 4. The lead as recited in claim 1, wherein the curved portion has a radius smaller than the radius associated with the inner wall of the atrium of the heart.
  • 5. The lead as recited in claim 1, further comprising:a third electrode positioned near the second electrode, said lead adapted for pacing and defibrillation of the heart.
  • 6. The lead as recited in claim 1, further comprising:a third electrode positioned near the first electrode; and a fourth electrode positioned near the second electrode, said lead adapted for pacing and defibrillation of the heart.
  • 7. The lead as recited in claim 6, wherein the third electrode positioned near the first electrode is a shocking coil.
  • 8. The lead as recited in claim 6, wherein the fourth electrode positioned near the second electrode is a shocking coil for positioning near the superior vena cava.
  • 9. The lead as recited in claim 8, further comprising a fifth electrode positioned near the second electrode, said fifth electrode used for atrial sensing within the atrium of the heart.
  • 10. The lead as recited in claim 1, wherein the outside of the lead body includes a textured portion for passive fixation of the lead to the heart.
  • 11. The lead as recited in claim 10, wherein the textured portion of the lead body is near the second electrode.
  • 12. The lead as recited in claim 1, the lead body defined in part by a first longitudinal axis;and the second electrode protruding outwardly from the lead body, said second electrode defined in part by a second longitudinal axis, where the first longitudinal axis is disposed transverse to the first longitudinal axis.
  • 13. The lead as recited in claim 12, wherein the curved portion is disposed away from the lead body in a first direction, and the second electrode protrudes outwardly toward the first direction.
  • 14. The lead as recited in claim 12, wherein the ring electrode includes at least one small porous tip electrode disposed on a side surface of the ring electrode.
  • 15. The lead as recited in claim 12, wherein the ring electrode comprises a smooth ring.
  • 16. The lead as recited in claim 12, wherein the ring electrode includes two or more layers of conductive mesh attached thereto.
  • 17. The lead as recited in claim 12, wherein the ring electrode includes one or more layers of conductive mesh attached on a side surface of the ring electrode, where the layers are deposited on a thin band.
  • 18. The lead as recited in claim 12, wherein the first electrode has opposite polarity than the second electrode.
  • 19. The lead as recited in claim 1, wherein the second electrode is a porous ring having a diameter substantially the same as the lead body.
  • 20. The lead as recited in claim 19, wherein the second electrode comprises a porous ring.
  • 21. The lead as recited in claim 1, wherein the second electrode further comprises a plurality of raised ridges on said ring.
  • 22. The lead as recited in claim 1, wherein the ring is partially masked.
  • 23. A lead adapted for endocardial implantation on or about the heart and for connection to a system for monitoring or stimulating cardiac activity, said lead comprising:a lead body having a proximal end and a distal end; a first electrode attached to the distal end of the lead body; and a second electrode attached to the lead body a selected distance away from the first electrode, said lead body formed with a curve therein to facilitate positioning of the second electrode within the heart, the second electrode further comprising a passive fixation element wherein the second electrode includes an electrically conductive ring element.
  • 24. The lead adapted for endocardial implantation as recited in claim 23, wherein the first electrode is positioned within one chamber of the heart and the second electrode is positioned within another chamber of the heart.
  • 25. The lead adapted for endocardial implantation as recited in claim 23, wherein the electrically conductive ring has a diameter substantially the same as the lead body.
  • 26. The lead as recited in claim 23, wherein the lead body includes a textured portion positioned near the second electrode.
  • 27. A system for delivering signals to the heart, said system comprising:an electronics system further comprising: a cardiac activity sensor; and a signal generator which produces signals to stimulate the heart; and a lead adapted for endocardial implantation on or about the heart, and for connection to the electronics system, said lead comprising: a lead body having a proximal end and a distal end, and a curved portion at a selected distance from the distal end of the lead body; a first electrode attached to the lead body; and a second electrode attached to the lead body, said first electrode at the distal end of the lead body for contact with a first chamber of the heart and said second electrode positioned a distance from the first electrode on a curved portion of the lead body to facilitate attachment of the second electrode to the second chamber of the heart, said second electrode further comprising a passive fixation element wherein the second electrode includes an electrically conductive ring element.
  • 28. A lead comprising:a lead body extending from a proximal end to a distal end, the lead body having a curved portion at a selected distance from the distal end of the lead body, the lead body defined in part by a first longitudinal axis; a first electrode disposed at the distal end of the lead body; a second electrode attached to the lead body, said second electrode positioned a predetermined distance from the first electrode to facilitate attachment of the second electrode to a second chamber of the heart, where the second electrode protrudes outwardly from the lead body, said second electrode comprising a ring electrode defined in part by a second longitudinal axis, where the first longitudinal axis is disposed transverse to the first longitudinal axis; and wherein the ring electrode includes at least one small porous tip electrode.
  • 29. The lead as recited in claim 28, wherein the ring electrode includes a first small porous tip electrode and a second small porous tip electrode.
  • 30. The lead as recited in claim 29, wherein the ring electrode has an outer surface, and the first small porous tip electrode and the second small porous tip electrode are disposed on the outer surface 90 degrees from one another.
  • 31. The lead as recited in claim 28, wherein the ring electrode is defined by a first height and the at least one small porous tip electrode is defined in part by a first diameter, and the first diameter is greater than 50% of the first height.
  • 32. A lead comprising:a lead body extending from a proximal end to a distal end, the lead body having a curved portion at a selected distance from the distal end of the lead body, the lead body defined in part by a first longitudinal axis; a first electrode disposed at the distal end of the lead body; a second electrode attached to the lead body, said second electrode positioned a predetermined distance from the first electrode to facilitate attachment of the second electrode to a second chamber of the heart, where the second electrode protrudes outwardly from the lead body, said second electrode comprising a ring electrode defined in part by a second longitudinal axis, where the first longitudinal axis is disposed transverse to the first longitudinal axis; and wherein the ring electrode includes one or more layers of conductive mesh attached thereto.
  • 33. A lead comprising:a lead body extending from a proximal end to a distal end, the lead body having a curved portion at a selected distance from the distal end of the lead body, the lead body defined in part by a first longitudinal axis; a first electrode disposed at the distal end of the lead body; a second electrode attached to the lead body, said second electrode positioned a predetermined distance from the first electrode to facilitate attachment of the second electrode to a second chamber of the heart, where the second electrode protrudes outwardly from the lead body, said second electrode comprising a ring electrode defined in part by a second longitudinal axis, where the first longitudinal axis is disposed transverse to the first longitudinal axis; and wherein the ring electrode includes one or more layers of conductive mesh attached thereto, where the layers are deposited on a thin band.
  • 34. The lead as recited in claim 33, wherein the thin band is raised from an outer surface of the ring electrode.
  • 35. The lead as recited in claim 33, wherein the ring electrode is defined by a first portion comprising the thin band and a second portion comprising a remaining portion of the ring electrode, where the first portion is electrically active and the second portion is insulated.
US Referenced Citations (123)
Number Name Date Kind
3614955 Morowski Oct 1971
3804098 Friedman Apr 1974
3866615 Hewson Feb 1975
3926197 Alley, III Dec 1975
3942536 Mirowski et al. Mar 1976
4030508 Thalen Jun 1977
4030509 Heilman et al. Jun 1977
4106512 Bisping Aug 1978
4136703 Wittkampf Jan 1979
4154247 O'Neill May 1979
4170999 Allen et al. Oct 1979
4217913 Dutcher Aug 1980
4270549 Heilman Jun 1981
4291707 Heilman et al. Sep 1981
4299239 Weiss et al. Nov 1981
4311153 Smits Jan 1982
4463765 Gold Aug 1984
4548203 Tacker, Jr. et al. Oct 1985
4559951 Dahl et al. Dec 1985
4567900 Moore Feb 1986
4567901 Harris Feb 1986
4570642 Kane et al. Feb 1986
4603705 Speicher et al. Aug 1986
4624265 Grassi Nov 1986
4624266 Kane Nov 1986
4627439 Harris Dec 1986
4633880 Osypka et al. Jan 1987
4646755 Kane Mar 1987
4649937 DeHaan et al. Mar 1987
4649938 McArthur Mar 1987
4662377 Heilman et al. May 1987
4664113 Frisbie et al. May 1987
4721115 Owens Jan 1988
4727877 Kallok Mar 1988
4784161 Skalsky et al. Nov 1988
4799486 DuFault Jan 1989
4799493 DuFault Jan 1989
4817608 Shapland et al. Apr 1989
4817634 Holleman et al. Apr 1989
4819661 Heil, Jr. et al. Apr 1989
4819662 Heil, Jr. et al. Apr 1989
4827932 Ideker et al. May 1989
4860769 Fogarty et al. Aug 1989
4865037 Chin et al. Sep 1989
4886074 Bisping Dec 1989
4905691 Rydell Mar 1990
4924881 Brewer May 1990
4938231 Milijasevic et al. Jul 1990
4944300 Saksena Jul 1990
4953551 Mehra et al. Sep 1990
4962767 Brownlee Oct 1990
4967766 Bradshaw Nov 1990
4971070 Holleman et al. Nov 1990
4998975 Cohen et al. Mar 1991
5016645 Williams et al. May 1991
5016646 Gotthardt et al. May 1991
5016808 Heil, Jr. et al. May 1991
5020544 Dahl et al. Jun 1991
5044375 Bach, Jr. et al. Sep 1991
5050601 Kupersmith et al. Sep 1991
5056516 Spehr Oct 1991
5063932 Dahl et al. Nov 1991
5076285 Hess et al. Dec 1991
5083562 de Coriolis et al. Jan 1992
5105826 Smits et al. Apr 1992
5107834 Ideker et al. Apr 1992
5111811 Smits May 1992
5111812 Swanson et al. May 1992
5129404 Spehr et al. Jul 1992
5133353 Hauser Jul 1992
5133365 Heil, Jr. et al. Jul 1992
5152299 Soukup Oct 1992
5165403 Mehra Nov 1992
5174289 Cohen Dec 1992
5174303 Schroeppel Dec 1992
5203348 Dahl et al. Apr 1993
5209229 Gilli May 1993
5230337 Dahl et al. Jul 1993
5259394 Bens Nov 1993
5259395 Li Nov 1993
5261400 Bardy Nov 1993
5269319 Schulte et al. Dec 1993
5271417 Swanson et al. Dec 1993
5282845 Bush et al. Feb 1994
5300108 Rebell et al. Apr 1994
5300110 Latterell et al. Apr 1994
5314459 Swanson et al. May 1994
5324327 Cohen Jun 1994
5342414 Mehra Aug 1994
5344439 Otten Sep 1994
5358516 Myers et al. Oct 1994
5366496 Dahl et al. Nov 1994
5374286 Morris Dec 1994
5383908 Sweeney et al. Jan 1995
5397342 Heil, Jr. et al. Mar 1995
5405373 Petersson et al. Apr 1995
5411544 Mar et al. May 1995
5425755 Doan Jun 1995
5425756 Heil, Jr. et al. Jun 1995
5447533 Vachon et al. Sep 1995
5447534 Jammet Sep 1995
5456706 Pless et al. Oct 1995
5456708 Doan et al. Oct 1995
5476501 Stewart et al. Dec 1995
5492119 Abrams Feb 1996
5496362 KenKnight et al. Mar 1996
5500008 Fain Mar 1996
5514174 Heil, Jr. et al. May 1996
5522874 Gates Jun 1996
5531780 Vachon Jul 1996
5534022 Hoffmann et al. Jul 1996
5545205 Schulte et al. Aug 1996
5554178 Dahl et al. Sep 1996
5578068 Laske et al. Nov 1996
5628779 Bornzin et al. May 1997
5674274 Morgan et al. Oct 1997
5755761 Obino May 1998
5772693 Brownlee Jun 1998
5776072 Hsu et al. Jul 1998
5782898 Dahl et al. Jul 1998
5885221 Hsu et al. Mar 1999
5964795 McVenes et al. Oct 1999
6055457 Bonner Apr 2000
Foreign Referenced Citations (18)
Number Date Country
2827595 May 1978 DE
0573275 Dec 1993 EP
0620024 Oct 1994 EP
0813886 Dec 1997 EP
0057877 Aug 1982 EP
0211166 Feb 1987 EP
0452278 Oct 1991 EP
0460324 Dec 1991 EP
0612538 Aug 1994 EP
0672431 Sep 1995 EP
2588758 Apr 1987 FR
2240721 Aug 1991 GB
2032278 Jun 1980 GB
3-168161 Jul 1991 JP
4-40966 Feb 1992 JP
9207616 May 1992 WO
9615665 Nov 1994 WO
8906148 Jul 1989 WO
Non-Patent Literature Citations (8)
Entry
Fain, et al., “A New Internal Defibrillation Lead System: Intrapercardial Placement Without Thoracotomy”, Abstracts Circulation, 76, Suppl. IV, 1839 (Oct. 1987).
Jones, D.L., et al., “Internal Cardiac Defibrillation in Man: Pronounced Improvement with Sequential Pulse Delivery to Two Different Lead Orientations”, Circulation, vol. 73, No. 3, pp. 484-491 (Mar. 1986).
U.S. application No. 09/121,020, filed on Jul. 22, 1998 entitled “Single Pass Defibrillation/Pacing Lead with Passively Attached Electrode for Pacing and Sensing”.
U.S. application No. 09/1231,006, filed Jul. 22, 1998 entitled “Single Pass Lead Having Retractable, Actively Attached Electrode For Pacing and Sensing”.
U.S. application No. 09/121,019, filed Jul. 22, 1998 entitled “Single-Pass Endocardial Lead for Multi-Site Atrial Pacing”.
U.S. application No. 09/121,288, filed on Jul. 22, 1998 entitled “High Impedance Electrode Tip”.
U.S. application No. 09/120,824, filed on Jul. 22, 1998 entitled “Single Pass Lead System”.
U.S. application No. 09/121,005, filed on Jul. 22, 1998 entitled “Single Pass Lead and System with Active and Passive Fixation Elements”.